Rate My Professor Andrew Davies

His academic interests centre on haematological malignancies, with a particular emphasis on lymphoma, including diffuse large B-cell lymphoma and follicular lymphoma. Research specializations encompass the clinical evaluation of malignant lymphoma, development of novel therapeutic strategies such as monoclonal antibody-based treatments, biomarker discovery, and high-dose therapies with stem cell support. As Director of the Southampton Experimental Cancer Medicine Centre, funded by Cancer Research UK and the National Institute for Health and Care Research, he oversees translational research and leads multiple clinical trials from phase I to phase III, including pioneering first-in-human lymphoma studies. He serves as Chair of the UK National Cancer Research Institute Lymphoma Clinical Studies Group, former Chair of the High Grade Lymphoma Study Group, Wessex regional lead for Teenager and Young Adult cancers, and Clinical Lead for the Thames Valley and Wessex TYA Operational Delivery Network.

Professor Davies has made significant contributions to the field through high-impact publications and leadership in landmark trials. Notable works include "Subcutaneous Rituximab for the Treatment of B-Cell Lymphomas" (Davies et al., Blood Advances, 2017), "Double-hit Lymphoma: So What?" (Hematological Oncology, 2019), "Optimising Initial Treatment for Follicular Lymphoma" (The Lancet Oncology, 2008), "Tailoring Front-Line Therapy in Diffuse Large B-Cell Lymphoma" (Hematology, 2017), and "Randomised Phase II Study of Acalabrutinib in Combination with Rituximab" (Blood, 2025). His efforts have advanced personalized treatments, enhancing survival rates for patients with aggressive lymphomas via targeted immunotherapies and combination regimens.